logo
logo
TNDM stock ticker logo

Tandem Diabetes Care, Inc.

NASDAQ•TNDM
CEO: Mr. John F. Sheridan
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2013-11-14
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Contact Information
12400 High Bluff Drive, San Diego, CA, 92130, United States
858-366-6900
www.tandemdiabetes.com
Market Cap
$1.70B
P/E (TTM)
-8.2
26.3
Dividend Yield
--
52W High
$29.65
52W Low
$9.98
52W Range
75%
Rank61Top 91.5%
2.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$290.38M+0.00%
4-Quarter Trend

EPS

-$0.01+0.00%
4-Quarter Trend

FCF

$3.10M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Sales Growth Total sales reached $1.01B USD in 2025, marking a 7.9% increase over 2024 sales of $940.2M USD.
Gross Margin Expansion Gross margin improved to 54% in 2025, up from 52% in 2024, driven by better pricing and lower costs.
Major Litigation Settlement Recorded $20.0M litigation expense settling Roche Cross-License Agreement; IPR&D expense was $75.2M.

Risk Factors

Sustained Operating Losses Operating loss widened to $187.3M USD in 2025 from $99.1M USD in 2024 due to increased operating expenses.
Reimbursement Coverage Uncertainty Failure to secure adequate third-party payor coverage or reimbursement limits product acceptance and sales growth potential.
Supply Chain Dependency Risk Reliance on limited third-party suppliers for critical components risks supply continuity and harms business operations.
Cybersecurity Threat Exposure Systems vulnerable to cyberattacks, potentially causing data loss, operational disruption, and reputational harm across global operations.

Outlook

Pharmacy Channel Strategy Shift Implementing pay-as-you-go pharmacy benefit model in 2026 to increase adoption, offsetting initial decrease in pump sales.
Pipeline Innovation Focus Future technology includes tubeless patch pump option for Mobi and next-generation platform advancement for fully closed loop.
International Direct Sales Transition Transitioning international distribution to direct sales starting in UK and Austria during 2026 to enhance control.
Managing High Operating Costs Future capital needs depend on managing expenses related to R&D, sales expansion, and facility footprint growth.

Peer Comparison

Revenue (TTM)

EVH stock ticker logoEVH
$1.88B
-26.6%
IART stock ticker logoIART
$1.64B
+1.5%
TNDM stock ticker logoTNDM
$1.01B
-4.2%

Gross Margin (Latest Quarter)

URGN stock ticker logoURGN
91.3%
-2.2pp
XNCR stock ticker logoXNCR
90.9%
+0.0pp
PHAT stock ticker logoPHAT
86.7%
+1.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TNGX$2.26B-22.2-50.3%8.4%
TNDM$1.70B-8.2-142.0%64.0%
IRMD$1.27B56.423.8%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
7.4%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Deep Research

Next earnings:Apr 28, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data